Please login to the form below

Not currently logged in
Email:
Password:

New drug matches chemo performance

Swiss pharmaceutical company, Roche, has revealed that new data will be presented at the WCGI showing that patients taking capecitabine can live up to five years after bowel cancer surgery

Swiss pharmaceutical company, Roche, has revealed that new data will be presented at the World Congress on Gastrointestinal Cancer (WCGI) showing that patients taking capecitabine can live up to five years after bowel cancer surgery.

Marketed by Roche under the brand name, Xeloda, capecitabine is proving to be as efficacious at sustaining a patient's post cancer operative life span as current treatments. Currently, patients who undergo bowel cancer surgery will be required to visit hospitals on a regular basis to complete courses of chemotherapy, administered as an intravenous (IV) therapy option.

Roche says that Patients who take capecitabine, which is already approved in 100 countries as a cancer medication, will not have to go through a long and regular course of IV chemotherapy. According to the company, the medicine could help clinicians fulfil the pledges of the Cancer Reform Strategy by allowing patients to be treated in the comfort and dignity of their own homes.

"These data confirm that capecitabine is an excellent treatment option for patients, both in terms of survival and convenience," said Jim Cassidy, professor of oncology at the Beaston Oncology Centre in Glasgow.

"Now that we have long-term evidence showing that capecitabine is at least as effective as 5-FU/FA, this supports the case for us to update our clinical practice."

27th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics